SOST and stage 5 chronic kidney disease: We found significant lower serum sclerostin in dialysis patients with secondary hyperparathyroidism (Table 1; compared with the data of 12 patients with end-stage renal disease without hyperparathyroidism as laboratory internal control of sclerostin and DKK1, data not shown).